Recent molecular characterization of primary urothelial carcinoma (UC) may guide future
clinical decision-making. For metastatic UC (mUC), a comprehensive molecular …

Urothelial cancer (UC) care is moving toward precision oncology. For tumor biology–driven
treatment of metastatic UC (mUC), molecular subtypes play a crucial role. However, it is not …

BACKGROUND Little is known about the genomic differences between metastatic lower
tract urothelial carcinoma (LTUC) and upper tract urothelial carcinoma (UTUC). We compare …

Abstract Urothelial Cancer-Genomic Analysis to Improve Patient Outcomes and Research
(NCT02643043), UC-GENOME, is a genomic analysis and biospecimen repository study in …

Urothelial cancer of the urinary bladder frequently metastasizes to lymph‐nodes, lungs, liver
and bone. A taxonomy for molecular classification exists, but it is unknown if molecular …

The molecular characteristics of metastatic upper tract urothelial carcinoma (UTUC) are not
well understood, and there is a lack of knowledge regarding the genomic and transcriptomic …

PURPOSE: A better understanding of the molecular basis of urothelial carcinoma (UC) is
needed to refine the clinical decision-making process. METHODS AND MATERIALS: We …

Although urothelial carcinoma (UC) of the urinary bladder generally portends a favorable
prognosis, metastatic tumors often follow an aggressive clinical course. DNA was extracted …

BACKGROUND Biomarker‐guided clinical trials are increasingly common in metastatic
urothelial carcinoma (mUC), yet patients for whom contemporary tumor tissue is not …

Backgrounds Despite the genomic landscape of urothelial carcinomas (UC) patients,
especially those with UC of bladder (UCB), has been comprehensively delineated and …